Business Value: Vyome Therapeutics (HIND)
Market fluctuations in Vyome Holdings Inc (HIND) shares reflect an enterprise value of 6.02. Vyome Holdings Inc focuses on developing treatments for resistant skin pathologies to replace ineffective antibiotics. Unique patents and complex R&D serve as a moat, despite strict FDA oversight. The company is currently upgrading its facilities and utilizing laboratories to prepare for the mass production of its drugs.
%20Enterprise%20Value&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_HIND_-_Vyome-Holdings-Inc_-_Enterprise-Value "Vyome Holdings - HIND Business Value (period 11/23/2025 - 11/01/2026) | 👁️GURU.Markets👁️")
Vyome Holdings Inc (HIND) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- balance sheet net asset value indicators:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Vyome Holdings Inc|HIND - Long-Term Debt to Capital|Short-Term Debt to Capital reshapelifesciences.com|HIND - Company Debts|Debt to Net Assets Ratio Vyome Holdings|HIND - Company Long-Term Debt|Company Current Liabilities Vyome Holdings|Quick Ratio reshapelifesciences.com
- earnings and valuation multiples indicators:
Analysis of all company metrics:Vyome Holdings Inc.
To select assets with a high margin of safety, analyzing enterprise value—which sums market capitalization and debt, minus cash, to determine the total acquisition price of a business—is critically important. Amidst the intense R&D race for Vyome Holdings Inc (HIND), this metric reflects the real price of risk, as clearly demonstrated by the historical enterprise value chart.
Competitors of Vyome Holdings Inc (HIND)
Company Buyout Price argenx N.V. (ARGX)|BNTX - Total Company Value|ABVX (Abivax Pharma) - Business Value|ADMA: Enterprise Value|Business Value PTGX|Total Company Value Immunovant|Kiniksa Pharmaceuticals, Ltd. - Full Business Value|Enterprise Value GRFS|ADPT (Adaptive Biotechnologies Inc.) - Value Adjusted for Debt and Cash|Enterprise Value CLDX (Celldex Therapeutics)|Enterprise Value auriniapharma.com AUPH|BCRX - Total Company Value|Value Adjusted for Debt and Cash VERA (Vera Therapeutics Inc)|Dianthus Pharma (DNTH) - Total Company Value|Real Price to Acquire Entire Company Pharvaris Pharma|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com|Real Price to Acquire Entire Company PGEN (Precigen)|PHAR (Pharming Group NV) - Value Adjusted for Debt and Cash|Enterprise Value NKTR (Nektar)|Company Buyout Price Upstream Pharma (UPB)|ZBIO - Total Company Value|immunome.com (IMNM) - Real Price to Acquire Entire Company|Gossamer Bio (GOSS) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|Real Price to Acquire Entire Company SEPN|Enterprise Value Pieris Corp|Total Company Value Savara Inc. (SVRA)|rigel.com - Business Value|Enterprise Value ANAB (AnaptysBio)|Astria Therapeutics Inc (ATXS) - Total Enterprise Value|ENGN: Real Price to Acquire Entire Company|RAPT: Total Company Value|JBIO (aerovatetx.com) - Real Price to Acquire Entire Company|Total Enterprise Value aclaristx.com (ACRS)|Total Company Value Kyverna Therapeutics, Inc.|Total Enterprise Value Tiziana Life Sciences Ltd. TLSA|Total Company Value Cabaletta Bio, Inc (CABA)|Real Price to Acquire Entire Company Ventyx Biosciences, Inc VTYX|Enterprise Value THTX (Theratechnologies Inc.)|avalotx.com (AVTX) - Total Enterprise Value|ELDN: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash AGEN (Agenus, Inc.)|CLYM: Enterprise Value|Zura Bio Ltd - Value Adjusted for Debt and Cash|Total Company Value aTyr Pharma, Inc.|Total Enterprise Value Adagene Corp ADAG|Total Company Value ImageneBio Inc (IMA)|Total Company Value STTK (shattucklabs.com)|Enterprise Value EQ (Equillium)|CNTB: Business Value|Immunic Inc - Enterprise Value|Company Buyout Price Atara Biotherapeutics ATRA|inflarx.de (IFRX) - Total Company Value|Business Value XFOR|ACET (Adicet Bio Inc.) - Enterprise Value|CELU - Full Takeover Company Value|Total Company Value INmune Bio, Inc. (INMB)|Company Buyout Price barinthusbio.com|Kezar Life Sciences, Inc. - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash SABS|Akari Therapeutics plc - Enterprise Value|Company Buyout Price Enlivex Therapeutics ENLV|q32bio.com (QTTB) - Total Company Value|Business Value GOVX|EDSA (Edesa Biotech) - Enterprise Value|Real Price to Acquire Entire Company iBio Inc (IBIO)|Enterprise Value CARM|XTLB (XTL Bio) - Value Adjusted for Debt and Cash|Enterprise Value BOLT (Bolt Biotherapeutics, Inc.)|Company Buyout Price HCW Biologics, Inc. (HCWB)|APVO - Total Company Value|AIM (AIM ImmunoTech, Inc.) - Business Value|ADTX: Enterprise Value|Business Value GRI|Total Company Value XORTX Therapeutics Inc.|revbiosciences.com - Full Business Value|Enterprise Value INDP|SCNI (Scinai Immunotherapeutics Ltd) - Value Adjusted for Debt and Cash|Enterprise Value CALI (CalciMedica)|Enterprise Value Affimed NV AFMD|ALLK - Total Company Value|Value Adjusted for Debt and Cash HOOK (HOOKIPA Pharma Inc.)|igmbio.com (IGMS) - Total Company Value|Real Price to Acquire Entire Company iTeos Therapeutics Inc|OCEA (Ocean Bio) - Enterprise Value|Enterprise Value TC BioPharm Ltd|Real Price to Acquire Entire Company THRD (Third Harmonic Bio)